METHOD FOR SELECTING THERAPEUTIC APPROACH IN PATIENTS WITH SCHIZOPHRENIA Russian patent published in 2024 - IPC C12Q1/6827 C12Q1/6837 C12Q1/6858 A61K31/395 A61P25/18 

FIELD: medicine.

SUBSTANCE: invention relates to psychiatry and can be used to select a therapeutic approach to patients with schizophrenia. Individual selection and dosing of drugs for a specific patient is carried out based on data of a multivariate genetic test. Pharmacogenetic testing is carried out by means of microchips. Cumulative risk of developing antipsychotic-induced adverse reactions due to efflux disturbance of antipsychotics of 1^st, 2^nd and 3^rd generations, given in table 1, through blood-brain barrier and membrane of neurons is estimated by antipsychotic transporter proteins P-glycoprotein, Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 1, encoded by genes ABCB1, ABCG2, ABCC1 respectively. For this purpose, by testing 26 low-functional and non-functional allelic variants of genes ABCB1, ABCG2, ABCC1, presented in table 2, patient’s genotype, information on genetically determined transport of antipsychotics is determined according to table 3. Patients are divided into three types: slow conveyors, intermediate conveyors, common conveyors. Based on the test results, a list of antipsychotics is obtained, divided into four categories: “Use as directed” in homozygous carriage of full-functional allelic variants of genes in a patient; “Use with caution” in case of heterozygous carriage of low-functional allelic variants of genes; “Use with increased care and with more frequent monitoring” in case of homozygous carriage of low-functional allelic variants of genes; “Do not use” in non-functional allelic variants in a patient with homozygous carriage. Slow transporter type patients take the selected antipsychotic in the starting and target dose by at least 50% and lower than the average therapeutic dose. Patients with the intermediate transporter type take the selected antipsychotic in the starting and target dose not less than 25 % lower than the recommended average therapeutic dose. Patients with the common transporter type take the selected antipsychotic in the average therapeutic single and daily doses according to the current instructions for the given medicinal agent.

EFFECT: method provides the possibility of increasing the effectiveness of choosing a therapeutic approach in patients with mental disorders by creating a personalized strategy for selecting an antipsychotic before starting the therapy, dosage regimen, dose escalation rate and possibility of combination with other antipsychotics.

4 cl, 6 dwg, 3 ex